The hemophilias and their clinical management: reports in the 55th ASH annual meeting

VernacularTitle:血友病的临床治疗:第55届美国血液学会年会报道
Author: Xiaojing HU ; Jun HOU ; Jumei SHI
Publication Type:Journal Article
Keywords: Hemophilias; Therapy; ASH annual meeting
From: Journal of Leukemia & Lymphoma 2014;23(2):75-78
CountryChina
Language:Chinese
Abstract: Outcomes for patients with hemophilia have improved dramatically over the past 50 years.With the increased availability of safe clotting factor concentrates,the primary focus in clinical management is now the prevention of long-term complications,most notably the debilitating hemophilic arthropathy that is associated with severe disease.Definitive evidence of improved clinical results from primary prophylaxis started in young patients-with severe hemophilia A and a minimal bleeding history is presented.Furthermore,recent studies showing benefits for initiating prophylaxis in older adolescents and adults with established joint disease are examined.lnhibitors to factor Ⅷ are the most problematic complication of factor replacement therapy.Patient-specific and treatment-related factors that contribute to the risk of inhibitor formation are discussed and controversies and clinical evidence related to approaches for tolerance induction are reviewed.Immune tolerance induction is the proven method for eradication of inhibitors.This article reviews latest research presented at the 55th ASH annual meeting on the hemophilias and their clinical management.